Efficacy and safety of daily intake of apomorphine SL in men affected by erectile dysfunction and mild hyperprolactinemia: a prospective, open-label, pilot study

By Caruso S.   Intelisano G.   Farina M.   DiMari L.   Agnello C.   Giammusso B.  

Urology, Vol. 62, Iss. 5, 2003-11 ,pp. : 922-927

Elsevier

Access to resources Recommend Favorite

Adverse Events and Patient Tolerability of Apomorphine SL 2 and 3 mg: A Cross-Study Analysis of Phase II and III Studies

By Ralph D.J.   Sleep D.J.   Perdok R.J.   Padley R.J.  

European Urology Supplements, Vol. 1, Iss. 3, 2002-05 ,pp. : 21-27

Elsevier

Access to resources Recommend Favorite

Effects of Visual Sexual Stimuli and Apomorphine SL on Cerebral Activity in Men with Erectile Dysfunction

By Hagemann J.H.   Berding G.   Bergh S.   Sleep D.J.   Knapp W.H.   Jonas U.   Stief C.G.  

European Urology, Vol. 43, Iss. 4, 2003-04 ,pp. : 412-420

Elsevier

Access to resources Recommend Favorite

Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction

By Dula E.   Keating W.   Siami P.F.   Edmonds A.   O'neil J.   Buttler S.  

Urology, Vol. 56, Iss. 1, 2000-07 ,pp. : 130-135

Elsevier

Access to resources Recommend Favorite

The Role of Apomorphine SL in the Treatment of Erectile Dysfunction

By Montorsi F.  

European Urology Supplements, Vol. 1, Iss. 3, 2002-05 ,pp. : 4-11

Elsevier

Access to resources Recommend Favorite